Symbols

GRAL

Grail·NASDAQ

--(--)

GRAL fundamentals

GRAL Q4 2025 Earnings

Grail (GRAL) released its earnings on Feb 19, 2026: revenue was 43.60M (YoY +13.97%), beat estimates; EPS was -2.44 (YoY +15.57%), beat estimates.

Revenue / YoY

43.60M

+13.97%

EPS / YoY

-2.44

+15.57%

Report date

Feb 19, 2026

GRAL Earnings Call Summary for Q4,2025

NHS-Galleri Trial Successes: 20% reduction in Stage IV cancers in later rounds, fourfold increase in cancer detection rate, and no serious safety concerns.
Commercial Momentum: 36% test volume growth in 2025, 26% revenue growth, and 30% prescriber base expansion.
FDA PMA Submission: Completed in January 2026, with 12-month review period expected.
Financial Strength: $904.4 million cash runway, 2026 guidance: Galleri sales growth 22-32%, cash burn ≤$300 million.

Earnings

EPS

Revenue

Revenue & Expenses

GRAL has released its 2025 Q4 earnings report, with revenue of 43.60M, reflecting a YoY change of 13.97%, and net profit of -99.18M, showing a YoY change of -2.17%. The Sankey diagram below clearly presents GRAL's revenue sources and cost distribution.

Key Indicators

Grail (GRAL) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Grail (GRAL)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Grail (GRAL)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Grail (GRAL)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown